Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry

Publication

Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry

Journal Paper/Review - Aug 1, 2005

Brouwers E E M, Tibben M M, Jörger Markus, van Tellingen O, Rosing H, Schellens J H M, Beijnen J H

Citation

Brouwers E, Tibben M, Jörger M, van Tellingen O, Rosing H, Schellens J, Beijnen J. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Analytical and bioanalytical chemistry 2005; 382:1484-90.

Type

Journal Paper/Review (English)

Journal

Analytical and bioanalytical chemistry 2005; 382

Publication Date

Aug 1, 2005

Issn Print

1618-2642

Pages

1484-90

Brief description/objective

A method for sensitive determination of the anti-cancer agent oxaliplatin in human plasma and human plasma ultrafiltrate (pUF) is presented. The method is based on the quantification of platinum by graphite-furnace atomic-absorption spectrometry, with Zeeman correction and an atomisation temperature of 2,700 degrees C. Sample pretreatment involves dilution of the samples with a solution containing 0.15 mol L(-1) NaCl and 0.20 mol L(-1) HCl in water. Validation was performed in accordance with the most recent FDA guidelines for bioanalytical method validation. All results were within requirements. The validated ranges of quantification were 0.10-400 micromol L(-1) for human pUF and 0.50-400 micromol L(-1) for plasma. The assay is now successfully used to support pharmacokinetic studies of cancer patients treated with oxaliplatin.